Physician profile
Scott A Baker
NPI 1285625210
$3,994.88
in general payments reported to CMS, 2019-2025
23 companies · $802 in 2025
The $802 reported for 2025 was more than what 75% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $334 · 2020: $335 · 2021: $512 · 2022: $472 · 2023: $681 · 2024: $860 · 2025: $802.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,195 · Education: $147.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,195.44 |
| Education | $146.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $948.18 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $733.83 | 2019-2025 | Dupixent |
| Glaxosmithkline, LLC. | $694.42 | 2021-2025 | Nucala |
| Inspire Medical Systems, INC. | $660.28 | 2020-2025 | Inspire |
| Acclarent, INC | $167.98 | 2019-2022 | |
| Optinose US, INC. | $119.43 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $118.85 | 2021-2024 | |
| Amgen INC. | $118.00 | 2019-2025 | Tezspire |
| Medtronic, INC. | $91.69 | 2021-2025 | Pteye Parathyroid Detection System |
| Stryker Corporation | $80.91 | 2019-2023 | Xpress Ent Dilation System |
| Supernus Pharmaceuticals, INC. | $42.90 | 2019-2020 | |
| Axsome Therapeutics, INC. | $32.92 | 2025 | Symbravo |
| Ambu INC. | $25.99 | 2023 | |
| Novartis Pharmaceuticals Corporation | $20.11 | 2023 | |
| Ethicon US, LLC | $19.93 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $18.96 | 2023 | |
| Aerin Medical INC. | $17.76 | 2020 | |
| Allergan, INC. | $16.78 | 2019 | |
| Kaleo, INC. | $14.36 | 2021 | |
| Pfizer INC. | $14.27 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.76 | 2025 | Eohilia |
| Smith+Nephew, INC. | $12.56 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $11.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.